

Electronic Supplementary Information

Assessing the stereoselectivity of *Serratia marcescens* CECT 977 2,3-butanediol dehydrogenase

Rosario Médici^a, Hanna Stammes^a, Stender Kwakernaak^a, Linda G. Otten^a, and Ulf Hanefeld^{a*}

^a Biocatalysis, Department of Biotechnology, Faculty of Applied Sciences, Delft University of Technology.

Van der Maasweg 9, 2629HZ Delft, The Netherlands.

Phone: +31 15 2789304

Fax: +31 15 2781415

* Corresponding author

Email: U.Hanefeld@tudelft.nl

Table of Contents

1. Chemicals and enzymes
2. Analytical methods
3. Synthesis of standards using Evocatal ADH-380 as biocatalyst
4. Synthesis of standards using BudC as biocatalyst
5. Supplementary figures
6. References

1. Chemicals and enzymes

Chemicals were purchased from Sigma-Aldrich (Schnelldorf, Germany), Acros Organics (Geel, Belgium) and used without further purification (*meso*-2,3-butanediol, (2*S*,3*S*)-2,3-butanediol, (2*R*,3*R*)-2,3-butanediol, *rac*-acetoin, 2,3-butanedione (diacetyl), (±)-1,3-butanediol, (±)-2,4-butanediol, 2,3-pentanedione, 3,4-hexanedione, 1,2-cyclohexanedione, (±)-*cis/trans*-1,2-cyclohexanediol, (±)-*trans*-1,2-cyclohexanediol, (1*S*,2*S*)-*trans*-1,2-cyclohexanediol, (1*R*,2*R*)-*trans*-1,2-cyclohexanediol, 1-phenyl-1,2-propanedione, benzil, *rac*-benzoin, (*R*)-benzoin). Media components were sourced from BD (Becton Dickinson B.V., Breda, The Netherlands).

(*R*)-2-hydroxy-1-phenylpropan-1-one ((*R*)-HPP) and (1*R*,2*R*)-1-phenylpropane-1,2-diol ((1*R*,2*R*)-PPD) were produced following the procedure reported by Jakoblinnert and Rother (2014),¹ whereas (*S*)-2-hydroxy-1-phenylpropan-1-one ((*S*)-HPP) was obtained according to Kihumbu *et al.*, (2002).² (*R*)-1-hydroxy-1-phenylpropan-2-one ((*R*)-PAC) was obtained according to Seth *et al.*, (2012).³ (1*S*,2*S*)-1-phenylpropane-1,2-diol ((1*S*,2*S*)-PPD)⁴ and (*S*)-1-hydroxy-1-phenylpropan-2-one ((*S*)-PAC).⁵

NAD(P)H oxidase (PRO-NOX(001), 0.1 U mg⁻¹) and formate dehydrogenase (PRO-FDH(001), 0.4 U mg⁻¹) were acquired from Prozomix as crude extract formulations. Glucose dehydrogenase and ADH-380 were acquired from Evocatal (Monheim am Rhein, Germany).

2. Analytical methods

¹H and ¹³C NMR spectra were recorded with an Agilent-400 MR DD2 instrument (400 MHz and 100 MHz, respectively). Chemical shifts (δ) are expressed in ppm, and coupling constants (*J*) are expressed in Hz. Optical rotations were determined at 25 °C with a Perkin-Elmer 241 polarimeter (sodium D line) and $[\alpha]$ values are in given in units 10⁻¹ deg cm² g⁻¹ and were in good accordance with reported data. Column chromatography was carried out with silica gel (0.060-0.200 mm, pore diameter ca. 6 nm) and Reveleris Silica Column (4g, Grace). Thin-layer chromatography (TLC) was performed on 0.20 mm silica gel 60-F plates. Compounds were visualized by treatment with a permanganate solution and heating.

Gas chromatography

α -Hydroxy ketone and diol formation and optical purity were monitored using chiral phase GC analysis. 1 μ L of the samples (split 1/100) was analyzed using a chiral CP-Chirasil-DEX

CB column (Varian, Germany; 25 m × 0.25 mm × 0.25 μm). The operating conditions were as follows: helium was the carrier gas; the temperature of the injector and detector (flame ionization detector (FID)) were set at 250 °C and 275 °C, respectively. HPP and PAC stereoisomers were also analysed by chiral GC employing a Lipodex E column, (Macherey-Nagel, Germany, 50 m × 0.25 mm × 0.25 μm). The operating conditions were as follows: helium as carrier gas; the temperature of the injector and detector (FID) were set at 200 °C and 225 °C, respectively. GC programs and retention times are detailed in Supplementary Table 1.

Supplementary Table 1: GC programs and retention times.

Column	Program ^a	Compound	Retention time (min)
A	60/7.5/10/85/1.5/10/100/1/10/125/1.5/25/225/1	diacetyl	3.0
		<i>R</i> -acetoin	9.7
		<i>S</i> -acetoin	10.6
		(<i>S,S</i>)-2,3-butanediol	16.5
		(<i>R,R</i>)-2,3-butanediol	16.8
		<i>meso</i> -2,3-butanediol	17.2
A	70/4/15/120/3/15/130/2/20/225/1	2,3-pentanedione	4.6
		(<i>R</i>)-2-hydroxypentan-3-one	8.2
		(<i>S</i>)-2-hydroxypentan-2-one	8.4
		(<i>S,S</i>)-2,3-pentanediol	11.7
A	70/2/15/130/5/15/225/1	2,3-hexanedione	4.8
		(<i>S</i>)-3-hydroxyhexan-2-one	8.1
A	70/4/15/130/5/15/225/2	3,4-hexanedione	6.0
		(<i>S</i>)-4-hydroxyhexan-3-one	9.6
		(<i>S,S</i>)-3,4-hexanediol	12.9
A	70/4/15/110/3/15/130/2/15/160/1/20/225/1	2,3-heptanedione	7.4
		(<i>R</i>)-2-hydroxyheptan-3-one	12.0
		(<i>S</i>)-2-hydroxyheptan-3-one	12.2
		3-hydroxyheptan-2-one	12.7
		(<i>S,R</i>)-2,3-heptanediol	15.9
A	140/30/25/225/1.5	1-phenyl-1,2-propanedione	4.8
		(<i>R</i>)-2-hydroxy-1-phenylpropan-1-one	8.8
		(<i>S</i>)-2-hydroxy-1-phenylpropan-1-one	9.3
		(<i>S</i>)-1-hydroxy-1-phenylpropan-2-one	10.1
		(<i>R</i>)-1-hydroxy-1-phenylpropan-2-one	9.3
		(1 <i>S</i> ,2 <i>S</i>)-1-phenylpropane-1,2-diol	25.7
		(1 <i>R</i> ,2 <i>R</i>)-1-phenylpropane-1,2-diol	27.4
		(1 <i>S</i> ,2 <i>R</i>)-1-phenylpropane-1,2-diol	28.9
		(1 <i>R</i> ,2 <i>S</i>)-1-phenylpropane-1,2-diol	29.7
B	90/3/8/140/8/20/220/1	(<i>R</i>)-2-hydroxy-1-phenylpropan-1-one	16.8
		(<i>S</i>)-2-hydroxy-1-phenylpropan-1-one	16.0
		(<i>S</i>)-1-hydroxy-1-phenylpropan-2-one	16.7
		(<i>R</i>)-1-hydroxy-1-phenylpropan-2-one	17.3

A	110/6/10/150/1/10/180/5/25/225/1	1,2-cyclohexanedione	7.8
		(<i>S,S</i>)- <i>trans</i> -1,2-cyclohexanediol	12.5
		<i>cis</i> -1,2-cyclohexanediol	12.7
		(<i>R,R</i>)- <i>trans</i> -1,2-cyclohexanediol	12.8

^a Program: initial temperature (°C) / hold time (min) / slope (°C/min) / temperature (°C) / hold time (min) / slope (°C/min) / temperature (°C) / hold time (min) / slope (°C/min) / temperature (°C) / hold time / slope (°C/min) / temperature (°C) / hold time. Column A: CP-Chirasil-DEX CB, column B: Lipodex E.

3. Synthesis of standards using Evoxx ADH-380 as biocatalyst

(a) Reduction of 2,3-pentanedione, **1a**.

After 24 h of incubation, (2*S*,3*S*)-2,3-pentanediol (**4a**) was chromatographed on a silica gel column using ethyl acetate as eluent with an overall yield of 12%. ¹H NMR (400 MHz, Chloroform-*d*): δ 3.68-3.51 (m, 1H), 3.25 (m, 1H), 2.44 (br s, 2H), 1.61-1.50 (m, 1H), 1.45-1.34 (m, 1H), 1.18 (d, *J*=6.4 Hz, 3H), 0.98 (t, *J*=7.4 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 77.50, 70.51, 26.15, 19.45, 9.86.⁶ $[\alpha]_D^{25} = -4.33$ (*c* 0.94, CHCl₃). lit.⁶ $[\alpha]_D^{22} = +4.5$ (*c* 1.0, CHCl₃) for (*R,R*)-2,3-pentanediol.

(b) Reduction of 3,4-hexanedione, **1c**.

After 48 h incubation, (3*S*,4*S*)-3,4-hexanediol (**4c**) was obtained in 25% isolated yield (eluent ethyl acetate). ¹H NMR (400 MHz, Chloroform-*d*): δ 3.38-3.29 (m, 2H), 2.38 (s, 2H), 1.67-1.35 (m, 4H), 0.97 (t, *J*=7.5 Hz, 6H). ¹³C NMR (101 MHz, CDCl₃): δ 75.46, 26.42, 9.96.⁷ $[\alpha]_D^{25} = -15.8$ (*c* 0.9, CHCl₃). lit.⁷ $[\alpha]_D^{25} = -16.5$ (*c* 0.03, CHCl₃).

(c) Reduction of 2,3-heptanedione, **1d**.

Following a similar procedure, (*S*)-2-hydroxyheptan-3-one (**2d**) was obtained in 21 % yield after 48 h incubation. The acyloin was isolated by chromatography on a silica gel column (eluent petroleum ether: ethyl acetate 7:3). ¹H NMR (400 MHz, Chloroform-*d*): δ 4.27-4.19 (m, 1H), 3.55 (d, *J*=4.7 Hz, 1H), 2.55-2.37 (m, 2H), 1.64-1.57 (m, 2H), 1.38 (d, *J*=7.1, 3H), 1.37-1.30 (m, 2H), 0.92 (t, *J*=7.3 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 212.64, 72.52, 37.21, 25.65, 22.32, 19.82, 13.75.⁸ $[\alpha]_D^{25} = +50.85$ (*c* 0.52, CHCl₃). lit.⁹ $[\alpha]_D^{25} = +59.2^\circ$, 88.7% *de* (*c* 0.9, CHCl₃).

(2*S*,3*R*)-2,3-heptanediol (**4d**) was eluted with ethyl acetate with an isolated yield of 7.3 %. ¹H NMR (400 MHz, Chloroform-*d*): δ 3.60 (p, *J*=6.3 Hz, 1H), 3.38-3.29 (m, 1H), 2.24 (br s, 2H), 1.57-1.22 (m, 6H), 1.19 (d, *J*=6.3 Hz, 3H), 0.92 (t, *J*=7.1, 3H).¹⁰ ¹³C NMR (101 MHz,

CDCl₃): δ 75.93, 70.61, 32.78, 27.44, 22.43, 19.23, 13.72. $[\alpha]_D^{25} = -18.2$ (*c* 0.4, CHCl₃).
lit.¹¹ $[\alpha]_D^{25} = -16.7$ (*c* 0.035, CHCl₃).

4. Synthesis of standards using BudC as biocatalyst

(a) Reduction of 2,3-heptanedione, **1d**.

After 48 h reaction, acyloins (**2-3d**) were isolated using flash column chromatography (Reveleris X², Grace, The Netherlands) using Reveleris Silica column (4g) and mixture of petroleum ether: ethyl acetate 98:2 (v/v) as eluent with an overall yield of 20 %. ¹³C NMR (101 MHz, CDCl₃): δ 212.64, 72.44, 37.04, 25.48, 22.17, 19.64, 13.62 corresponding to 2-hydroxy-3-heptanone (**2d**)⁸ and δ 210.04, 76.70, 33.07, 26.72, 25.01, 22.36, 13.72 corresponding to 3-hydroxy-2-heptanone (**3d**).¹²


(b) Reduction of 3,4-hexanedione, **1c**.

After 48 h incubation, (*S*)-4-hydroxyhexan-3-one (**2c**) was isolated in 15% yield after purification on a silica gel column (eluent petroleum ether: ethyl acetate 9:1 (v/v)). ¹H NMR (400 MHz, Chloroform-*d*) δ 4.20 – 4.12 (m, 1H), 2.58 – 2.34 (m, 2H), 1.88 (dq, *J* = 14.1, 7.5, 4.0 Hz, 1H), 1.67 – 1.51 (m, 1H), 1.10 (t, *J* = 7.3 Hz, 3H), 0.91 (t, *J* = 7.4 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 212.76, 76.96, 31.05, 26.81, 8.80, 7.55.¹³ $[\alpha]_D^{25} = +98.2$ (*c* 0.39, CHCl₃). lit.¹⁴ $[\alpha]_D^{22} = -97.5$ (*c* 1.0, CHCl₃) for (*R*)-4-hydroxyhexan-3-one.


(c) Reduction of 2,3-hexanedione (**1b**),

After 24 h reaction, (*S*)-3-hydroxyhexan-2-one (**3b**) was produced in 45% yield. Isolation was carried out using flash column chromatography (Reveleris X², Grace, The Netherlands) using Reveleris Silica column (4g) and petroleum ether: ethyl acetate mixture of 8:2 (v/v). ¹H NMR (400 MHz, Chloroform-*d*): δ 4.12 (dd, *J* = 7.3, 3.7 Hz, 1H), 2.14 (s, 3H), 1.83–1.65 (m, 1H), 1.54 – 1.25 (m, 3H), 0.89 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃): 210.06, 76.63, 35.55, 25.11, 18.04, 13.80.¹⁵ $[\alpha]_D^{25} = +101$ (*c* 0.6, CHCl₃). lit.¹⁵ $[\alpha]_D^{25} = -110.0$ (*c* 0.8, CHCl₃) for (*R*)-3-hydroxyhexan-2-one.


5. Supplementary Figures




Supplementary Figure 1: BudC activity of *E. coli* BL21 star pET-28a *budC* cell-free extracts for *rac*-acetoin: 50 mM *rac*-acetoin, NADH 0.16 mM, enzyme solution (1 μ l, 0.52 mg ml⁻¹) in potassium phosphate buffer (50 mM, pH 7.0). Cell-free extracts of *E. coli* BL21 star pET-28a (empty vector) were used as a negative control. 0.15 U mg⁻¹ of dehydrogenase activity was determined in the latter protein solution.



Supplementary Figure 2: Coomassie Blue stained native (left) and SDS-PAGE (right) of BudC after recombinant gene expression in *E. coli* and subsequent protein purification, respectively. Native gel: lane m: protein marker, lane 1: purified BudC. SDS-PAGE gel: lane m: protein marker, lane 1: total protein, lane 2: soluble fraction, lane 3: insoluble fraction, lane 4: purified BudC.




Supplementary Figure 3: Gas chromatogram of reaction standards at 5 mM.




Supplementary Figure 4: BudC initial rates vs substrate/nicotinamide cofactor concentration
 A) *meso*-2,3-butanediol, B) diacetyl, C) acetoin, D) NAD⁺. Michaelis-Menten curves of


substrates converted by BudC at pH 7.0. Reaction conditions are described in the *Experimental Section*. Error bars represent the standard deviation of three independent experiments.




Supplementary Figure 5: BudC relative activity vs NADH concentration.




Supplementary Figure 6: GC traces *R*-, *S*-HPP and *S*-, *R*-PAC standards with Column A (left figure) and Column B (right figure); *R*-HPP, *S*-HPP, *R*-PAC, *S*-PAC.




Supplementary Figure 7: GC chromatograms of 2,3-pentanedione (**1a**) standard reduction reactions catalysed by BudC (black and green traces) and ADH-380 (blue trace). Retention times: internal standard: 7.5 min; (2S,3S)-2,3-pentanediol (**4a**): 11.7 min.





Supplementary Figure 8: GC chromatograms of 2,3-hexanedione (**1b**) standard reduction reactions catalysed by BudC (blue trace, preparative scale), and ADH-380 (green trace). Black trace corresponds to the purified product (S)-3-hydroxyhexan-2-one (**3b**). Retention times: internal standard: 6.1 min; (S)-3-hydroxyhexan-2-one (**3b**): 8.1 min; putative 2,3-hexanediol (**4b**): 11.5 min.





Supplementary Figure 9: GC chromatograms of 3,4-hexanedione (**1c**) standard reduction reactions catalysed by BudC (green and black traces (2h and 24 h reaction, respectively), and ADH-380 (blue trace, 24 h). Red trace corresponds to the blank reaction. Retention times: 3,4-hexanedione (**1c**): 6 min; internal standard: 7.5 min; (*S*)-4-hydroxyhexan-3-one (**2c**): 9.6 min; (3*S*,4*S*)-3,4-hexanediol (**4c**): 12.9 min.





Supplementary Figure 10: GC chromatograms of 2,3-heptanedione (**1d**) standard reduction reactions catalysed by BudC (blue and black traces (2h and 24 h reaction, respectively), and ADH-380 (green trace, 24 h). Retention times: 2,3-heptanedione (**1d**): 7.4 min; internal standard: 7.7 min; (*R*)-2-hydroxyheptan-3-one: 12.0 min; (*S*)-2-hydroxyheptan-3-one (**2d**) : 12.2 min; 3-hydroxy-2-heptanone (**3d**): 12.7 min; (2*S*,3*R*)-2,3-heptanediol (**4d**): 15.8 min.




Supplementary Figure 11: ^{13}C and ^1H NMR of (*S,S*)-2,3-pentanediol (**4a**). Acetone signals were not assigned and marked in grey.




Supplementary Figure 12: ¹³C and ¹H NMR of (S)-3-hydroxy-2-hexanone (**3b**). Ethyl acetate signals were not assigned.




Supplementary Figure 13: ¹³C and ¹H NMR of (S)-4-hydroxy-3-hexanone (2c).




Supplementary Figure 14: ^{13}C and ^1H NMR of (*S,S*)-3,4-hexanediol (**4c**).




Supplementary Figure 15: ¹³C and ¹H NMR of (*S,R*)-2,3-heptanediol (**4d**).




Supplementary Figure 16: ¹³C and ¹H NMR of (*S*)-2-hydroxyheptan-3-one (2d).



Supplementary Figure 17: ¹³C NMR mixture 2-hydroxy-3-heptanone (**2d**) and 3-hydroxy-2-heptanone (**3d**). Ethyl acetate signals are marked in grey.



Supplementary Figure 18: Homology model of BudC based on the *meso*-2,3-butanediol dehydrogenase from *Klebsiella pneumoniae* (1GEG). The enzyme is a tetramer with NADH (ball and sticks) bound to each active site.



Supplementary Figure 19: Homology model BudC monomer showing the Rossmann fold binding the nicotinamide cofactor.

6. References

1. A. Jakoblinnert and D. Rother, *Green Chem.*, 2014, **16**, 3472-3482.
2. S. T. Kihumbu D, Hummel W, Liese A., *Tetrahedron: Asymmetry*, 2002, **13**, 1069-1072.
3. T. Sehl, R. C. Simon, H. C. Hailes, J. M. Ward, U. Schell, M. Pohl and D. Rother, *J. Biotechnol.*, 2012, **159**, 188-194.
4. J. Wachtmeister, P. Mennicken, A. Hunold and D. Rother, *Chemcatchem*, 2016, **8**, 607-614.
5. T. Sehl, S. Bock, L. Marx, Z. Maugeri, L. Walter, R. Westphal, C. Vogel, U. Menyes, M. Erhardt, M. Müller, M. Pohl and D. Rother, *Green Chem.*, 2017, **19**, 380-384.
6. D. Enders and S. Nakai, *Chem. Ber.*, 1991, **124**, 219-226.
7. P. Boutoute, G. Mousset and H. Veschambre, *New J. Chem.*, 1998, **22**, 247-251.
8. J. S. Dickschat, S. Wickel, C. J. Bolten, T. Nawrath, S. Schulz and C. Wittmann, *Eur. J. Org. Chem.*, 2010, **2010**, 2687-2695.
9. C. Loderer and M. B. Ansorge-Schumacher, *RSC Adv.*, 2015, **5**, 38271-38276.
10. W. Kroutil, M. Mischitz and K. Faber, *J. Chem. Soc., Perkin Trans. 1*, 1997, **1997**, 3629-3636.
11. F. Freire, J. M. Seco, E. Quinoa and R. Riguera, *J. Org. Chem.*, 2005, **70**, 3778-3790.
12. W. Chai, A. Takeda, M. Hara, S.-J. Ji and C. A. Horiuchi, *Tetrahedron*, 2005, **61**, 2453-2463.
13. K. Dong, R. Sang, J. F. Soule, C. Bruneau, R. Franke, R. Jackstell and M. Beller, *Chem. Eur. J.*, 2015, **21**, 18033-18037.
14. B. B. Lohray and D. Enders, *Helv. Chim. Acta*, 1989, **72**, 980-984.
15. F. Schröder, R. Fettköther, U. Noldt, K. Dettner, W. A. König and W. Francke, *Liebigs Ann. Chem.*, 1994, **1994**, 1211-1218.